CoChat

Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes

Lewin, Matthew R., Carter, Rebecca W., Matteo, Isabel A., Samuel, Stephen P., Rao, Sunita, Fry, Bryan G., Bickler, Philip E. · 2022 · Toxins
Cited by 98

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The availability of effective, reliably accessible, and affordable treatments for snakebite envenoming is a critical and long unmet medical need. Recently, small, synthetic toxin-specific inhibitors with oral bioavailability used in conjunction with antivenom have been identified as having the potential to greatly improve outcomes after snakebite. Varespladib, a small, synthetic molecule that broadly and potently inhibits secreted phospholipase A2 (sPLA2s) venom toxins has renewed interest in this class of inhibitors due to its potential utility in the treatment of snakebite envenoming. The development of varespladib and its oral dosage form, varespladib-methyl, has been accelerated by previous clinical development campaigns to treat non-envenoming conditions related to ulcerative colitis, rheumatoid arthritis, asthma, sepsis, and acute coronary syndrome. To date, twenty-nine clinical studies evaluating the safety, pharmacokinetics (PK), and efficacy of varespladib for non-snakebite envenoming conditions have been completed in more than 4600 human subjects, and the drugs were generally well-tolerated and considered safe for use in humans. Since 2016, more than 30 publications describing the structure, function, and efficacy of varespladib have directly addressed its potential for the treatment of snakebite. This review summarizes preclinical findings and outlines the scientific support, the potential limitations, and the next steps in the development of varespladib’s use as a snakebite treatment, which is now in Phase 2 human clinical trials in the United States and India.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/toxins14110783

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 88

  1. Calvete, 2017, Snakebite Envenoming, Nat. Rev. Dis. Primers, 3, 17063, 10.1038/nrdp.2017.63 · DOI · Paper page
  2. Longbottom, 2018, Vulnerability to Snakebite Envenoming: A Global Mapping of Hotspots, Lancet, 392, 673, 10.1016/S0140-6736(18)31224-8 · DOI · Paper page
  3. Vaiyapuri, S., Vaiyapuri, R., Ashokan, R., Ramasamy, K., Nattamaisundar, K., Jeyaraj, A., Chandran, V., Gajjeraman, P., Baksh, M.F., and Gibbins, J.M. (2013). Snakebite and Its Socio-Economic Impact on the Rural Population of Tamil Nadu, India. PLoS ONE, 8. · DOI · Paper page
  4. Williams, D.J., Faiz, M.A., Abela-Ridder, B., Ainsworth, S., Bulfone, T.C., Nickerson, A.D., Habib, A.G., Junghanss, T., Fan, H.W., and Turner, M. (2019). Strategy for a Globally Coordinated Response to a Priority Neglected Tropical Disease: Snakebite Envenoming. PLoS Negl. Trop. Dis., 13. · DOI · Paper page
  5. Harrison, R., and Gutiérrez, J. (2016). Priority Actions and Progress to Substantially and Sustainably Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite. Toxins, 8. · DOI
  6. Mohapatra, B., Warrell, D.A., Suraweera, W., Bhatia, P., Dhingra, N., Jotkar, R.M., Rodriguez, P.S., Mishra, K., Whitaker, R., and Jha, P. (2011). Snakebite Mortality in India: A Nationally Representative Mortality Survey. PLoS Negl. Trop. Dis., 5. · DOI · Paper page
  7. Gerardo, 2019, Does This Patient Have a Severe Snake Envenomation?, JAMA Surg., 154, 346, 10.1001/jamasurg.2018.5069 · DOI
  8. Ozay, 2005, Clinical Characteristics of Children with Snakebite Poisioning and Management of Complications in the Pediatric Intensive Care Unit, Pediatr. Int., 47, 669, 10.1111/j.1442-200x.2005.02134.x · doi:10.1111/j.1442-200x.2005.02134.x
  9. Samprathi, 2020, Epidemiology and Outcomes of Early Morning Neuroparalytic Syndrome Following Snake Bite—A Retrospective Study, J. Trop. Pediatr., 66, 435, 10.1093/tropej/fmz084 · doi:10.1093/tropej/fmz084
  10. Karthika, 2021, Neurotoxic Snake Envenomation: Neostigmine-Induced Paradoxical Weakness, Indian J. Pediatr., 88, 406, 10.1007/s12098-020-03602-7 · doi:10.1007/s12098-020-03602-7
  11. Pach, 2021, Paediatric Snakebite Envenoming: Recognition and Management of Cases, Arch. Dis. Child, 106, 14, 10.1136/archdischild-2020-319428 · doi:10.1136/archdischild-2020-319428
  12. Suryanarayana, G., Rameshkumar, R., and Mahadevan, S. (2021). Retrospective Hospital-Based Cohort Study on Risk Factors of Poor Outcome in Pediatric Snake Envenomation. J. Trop. Pediatr., 67. · doi:10.1093/tropej/fmaa078
  13. Variawa, 2021, Prospective Review of Cytotoxic Snakebite Envenomation in a Paediatric Population, Toxicon, 190, 73, 10.1016/j.toxicon.2020.12.009 · doi:10.1016/j.toxicon.2020.12.009
  14. Tasoulis, T., and Isbister, G.K. (2017). A Review and Database of Snake Venom Proteomes. Toxins, 9. · DOI · Paper page
  15. Pach, 2020, Paediatric Snakebite Envenoming: The World’s Most Neglected “Neglected Tropical Disease”?, Arch. Dis. Child, 105, 1135, 10.1136/archdischild-2020-319417 · doi:10.1136/archdischild-2020-319417
  16. Rucavado, 2018, Unresolved Issues in the Understanding of the Pathogenesis of Local Tissue Damage Induced by Snake Venoms, Toxicon, 148, 123, 10.1016/j.toxicon.2018.04.016 · DOI
  17. Montecucco, 2008, Cellular Pathology Induced by Snake Venom Phospholipase A 2 Myotoxins and Neurotoxins: Common Aspects of Their Mechanisms of Action, Cell. Mol. Life Sci., 65, 2897, 10.1007/s00018-008-8113-3 · DOI · Paper page
  18. Lomonte, 2012, Snake Venom Lys49 Myotoxins: From Phospholipases A2 to Non-Enzymatic Membrane Disruptors, Toxicon, 60, 520, 10.1016/j.toxicon.2012.02.007 · DOI · Paper page
  19. Lomonte, 2013, Phospholipases A2: Unveiling the Secrets of a Functionally Versatile Group of Snake Venom Toxins, Toxicon, 62, 27, 10.1016/j.toxicon.2012.09.006 · DOI · Paper page
  20. Mora, J., Mora, R., Lomonte, B., and Gutiérrez, J.M. (2008). Effects of Bothrops Asper Snake Venom on Lymphatic Vessels: Insights into a Hidden Aspect of Envenomation. PLoS Negl. Trop. Dis., 2. · DOI · Paper page
  21. Lewin, 2019, Neutralizing Properties of LY315920 toward Snake Venom Group I and II Myotoxic Phospholipases A2, Toxicon, 157, 1, 10.1016/j.toxicon.2018.11.292 · DOI · Paper page
  22. Salvador, 2021, The Synthetic Varespladib Molecule Is a Multi-Functional Inhibitor for PLA2 and PLA2-like Ophidic Toxins, Biochim. Et Biophys. Acta (BBA) Gen. Subj., 1865, 129913, 10.1016/j.bbagen.2021.129913 · DOI
  23. Salvador, 2019, Structural Basis for Phospholipase A2-like Toxin Inhibition by the Synthetic Compound Varespladib (LY315920), Sci. Rep., 9, 17203, 10.1038/s41598-019-53755-5 · DOI · Paper page
  24. Clare, 2021, Small Molecule Drug Discovery for Neglected Tropical Snakebite, Trends Pharmacol. Sci., 42, 340, 10.1016/j.tips.2021.02.005 · DOI · Paper page
  25. Laustsen, 2016, From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy, Curr. Pharm. Des., 22, 5270, 10.2174/1381612822666160623073438 · DOI · Paper page
  26. Bulfone, 2018, Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite, J. Trop. Med., 2018, 1, 10.1155/2018/4320175 · DOI · Paper page
  27. Williams, H.F., Mellows, B.A., Mitchell, R., Sfyri, P., Layfield, H.J., Salamah, M., Vaiyapuri, R., Collins-Hooper, H., Bicknell, A.B., and Matsakas, A. (2019). Mechanisms Underpinning the Permanent Muscle Damage Induced by Snake Venom Metalloprotease. PLoS Negl. Trop. Dis., 13. · DOI
  28. Prasarnpun, 2005, Envenoming Bites by Kraits: The Biological Basis of Treatment-Resistant Neuromuscular Paralysis, Brain, 128, 2987, 10.1093/brain/awh642 · DOI
  29. Senji Laxme, R.R., Khochare, S., de Souza, H.F., Ahuja, B., Suranse, V., Martin, G., Whitaker, R., and Sunagar, K. (2019). Beyond the ‘Big Four’: Venom Profiling of the Medically Important yet Neglected Indian Snakes Reveals Disturbing Antivenom Deficiencies. PLoS Negl. Trop. Dis., 13. · DOI · Paper page
  30. Abraham, 2003, Efficacy and Safety of LY315920Na/S-5920, a Selective Inhibitor of 14-KDa Group IIA Secretory Phospholipase A2, in Patients with Suspected Sepsis and Organ Failure, Crit. Care Med., 31, 718, 10.1097/01.CCM.0000053648.42884.89 · DOI
  31. Dennis, 2011, Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention, Chem. Rev., 111, 6130, 10.1021/cr200085w · DOI · Paper page
  32. Bickler, P.E. (2020). Amplification of Snake Venom Toxicity by Endogenous Signaling Pathways. Toxins, 12. · DOI
  33. Ranawaka, U.K., Lalloo, D.G., and de Silva, H.J. (2013). Neurotoxicity in Snakebite—The Limits of Our Knowledge. PLoS Negl. Trop. Dis., 7. · DOI · Paper page
  34. Quartino, 2018, Intravascular Hemolysis Induced by Phospholipases A 2 from the Venom of the Eastern Coral Snake, Micrurus Fulvius: Functional Profiles of Hemolytic and Non-Hemolytic Isoforms, Toxicol. Lett., 286, 39, 10.1016/j.toxlet.2017.11.037 · DOI
  35. Berling, 2015, Hematologic Effects and Complications of Snake Envenoming, Transfus. Med. Rev., 29, 82, 10.1016/j.tmrv.2014.09.005 · DOI · Paper page
  36. Noutsos, 2019, Snakebite Associated Thrombotic Microangiopathy: A Protocol for the Systematic Review of Clinical Features, Outcomes, and Role of Interventions, Syst. Rev., 8, 212, 10.1186/s13643-019-1133-2 · DOI
  37. Sitprija, 2008, Animal Toxins and the Kidney, Nat. Clin. Pract. Nephrol., 4, 616, 10.1038/ncpneph0941 · DOI
  38. Gopalakrishnan, 2019, Snake Envenoming─An Underreported Cause of Acute Kidney Injury, Kidney Int. Rep., 4, 643, 10.1016/j.ekir.2019.03.014 · doi:10.1016/j.ekir.2019.03.014
  39. Alfred, 2019, Acute Kidney Injury Following Eastern Russell’s Viper (Daboia siamensis) Snakebite in Myanmar, Kidney Int. Rep., 4, 1337, 10.1016/j.ekir.2019.05.017 · doi:10.1016/j.ekir.2019.05.017
  40. Krishnamurthy, 2015, Russell’s Viper Envenomation-Associated Acute Kidney Injury in Children in Southern India, Indian Pediatr., 52, 583, 10.1007/s13312-015-0679-x · doi:10.1007/s13312-015-0679-x
  41. Kumar, 2022, Snake Envenomation-Induced Acute Kidney Injury: Prognosis and Long-Term Renal Outcomes, Postgrad Med. J., 98, 264, 10.1136/postgradmedj-2020-139021 · DOI
  42. Harshavardhan, 2013, A Study on the Acute Kidney Injury in Snake Bite Victims in a Tertiary Care Centre, J. Clin. Diagn. Res., 7, 853
  43. Villalta, 2019, Nephrotoxicity Induced by the Venom of Hypnale Hypnale from Sri Lanka: Studies on Isolated Perfused Rat Kidney and Renal Tubular Cell Lines, Toxicon, 165, 40, 10.1016/j.toxicon.2019.04.014 · DOI
  44. Vuong, N.T., Jackson, T.N.W., and Wright, C.E. (2021). Role of Phospholipases A2 in Vascular Relaxation and Sympatholytic Effects of Five Australian Brown Snake, Pseudonaja spp., Venoms in Rat Isolated Tissues. Front. Pharmacol., 12. · DOI
  45. Arroyo, 1986, Pathogenesis of Myonecrosis Induced by Coral Snake (Micrurus nigrocinctus) Venom in Mice, Br. J. Exp. Pathol., 67, 1
  46. Xiao, H., Li, H., Zhang, D., Li, Y., Sun, S., Huang, C., Xiao, H., Li, H., Zhang, D., and Li, Y. (2018). Inactivation of Venom PLA2 Alleviates Myonecrosis and Facilitates Muscle Regeneration in Envenomed Mice: A Time Course Observation. Molecules, 23. · DOI
  47. Neale, 2018, Spine-Bellied Sea Snake (Hydrophis curtus) Venom Shows Greater Skeletal Myotoxicity Compared with Cardiac Myotoxicity, Toxicon, 143, 108, 10.1016/j.toxicon.2018.01.009 · doi:10.1016/j.toxicon.2018.01.009
  48. Lago, 2012, Myotoxicity and Nephrotoxicity by Micrurus Venoms in Experimental Envenomation, Toxicon, 59, 356, 10.1016/j.toxicon.2011.11.009 · DOI
  49. Ownby, 2003, Skeletal Muscle Degeneration Induced by Venom Phospholipases A2: Insights into the Mechanisms of Local and Systemic Myotoxicity, Toxicon, 42, 915, 10.1016/j.toxicon.2003.11.005 · DOI · Paper page
  50. Johnston, 2013, Mulga Snake (Pseudechis australis) Envenoming: A Spectrum of Myotoxicity, Anticoagulant Coagulopathy, Haemolysis and the Role of Early Antivenom Therapy—Australian Snakebite Project (ASP-19), Clin. Toxicol. (Phila), 51, 417, 10.3109/15563650.2013.787535 · doi:10.3109/15563650.2013.787535
  51. Burnouf, 2014, A Multicomponent Strategy to Improve the Availability of Antivenom for Treating Snakebite Envenoming, Bull. World Health Organ., 92, 526, 10.2471/BLT.13.132431 · DOI
  52. (2019). Williams; Layfield; Vallance; Patel; Bicknell; Trim; Vaiyapuri The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites. Toxins, 11. · DOI
  53. Lewin, M., Samuel, S., Merkel, J., and Bickler, P. (2016). Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins, 8. · DOI · Paper page
  54. (2011). Adis R&D Profile Varespladib. Adis R&D Insight, 11, 137–143. · DOI · Paper page
  55. Wery, 1991, Structure of Recombinant Human Rheumatoid Arthritic Synovial Fluid Phospholipase A2 at 2.2 A Resolution, Nature, 352, 79, 10.1038/352079a0 · doi:10.1038/352079a0
  56. Rosenson, 2010, Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients, J. Am. Coll. Cardiol., 56, 1079, 10.1016/j.jacc.2010.06.015 · DOI
  57. Nicholls, 2012, Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial, Cardiovasc. Drugs Ther., 26, 71, 10.1007/s10557-011-6358-9 · DOI
  58. Santoso, 2020, Phospholipase A2 Is an Inflammatory Predictor in Cardiovascular Diseases: Is There Any Spacious Room to Prove the Causation?, Curr. Cardiol. Rev., 16, 3, 10.2174/1573403X15666190531111932 · DOI
  59. 2014, Acute Coronary Syndromes: Targeting Inflammation-What Has the VISTA-16 Trial Taught Us?, Nat. Rev. Cardiol., 11, 130, 10.1038/nrcardio.2013.220 · DOI
  60. Nicholls, 2014, Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome, JAMA, 311, 252, 10.1001/jama.2013.282836 · DOI · Paper page
  61. Wang, Y., Zhang, J., Zhang, D., Xiao, H., Xiong, S., and Huang, C. (2018). Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules, 23. · DOI · Paper page
  62. Lewin, M.R.M.R.M.R., Gutiérrez, J.M., Samuel, S.P.S.P.S.P., Herrera, M., Bryan-Quirós, W., Lomonte, B., Bickler, P.E.P.E.P.E., Bulfone, T.C.T.C., Williams, D.J.D.J.D.J., and María Gutiérrez, J. (2018). Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus Scutellatus) Venom. Toxins, 10. · DOI · Paper page
  63. Lewin, M.R.M.R., Gilliam, L.L.L., Gilliam, J., Samuel, S.P.S.P., Bulfone, T.C.T.C., Bickler, P.E.P.E., and Gutiérrez, J.M.J.M. (2018). Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus Fulvius (Eastern Coral Snake) Venom. Toxins, 10. · DOI · Paper page
  64. Bittenbinder, M.A., Zdenek, C.N., op den Brouw, B., Youngman, N.J., Dobson, J.S., Naude, A., Vonk, F.J., and Fry, B.G. (2018). Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib). Toxins, 10. · DOI · Paper page
  65. Zdenek, 2019, Clinical Implications of Convergent Procoagulant Toxicity and Differential Antivenom Efficacy in Australian Elapid Snake Venoms, Toxicol. Lett., 316, 171, 10.1016/j.toxlet.2019.08.014 · DOI
  66. Zdenek, 2020, Anticoagulant Activity of Black Snake (Elapidae: Pseudechis) Venoms: Mechanisms, Potency, and Antivenom Efficacy, Toxicol. Lett., 330, 176, 10.1016/j.toxlet.2020.05.014 · DOI
  67. Alangode, 2020, Sodium Oleate, Arachidonate, and Linoleate Enhance Fibrinogenolysis by Russell’s Viper Venom Proteinases and Inhibit FXIIIa; a Role for Phospholipase A2 in Venom Induced Consumption Coagulopathy, Toxicon, 186, 83, 10.1016/j.toxicon.2020.07.011 · DOI
  68. Xie, C., Albulescu, L.-O.O., Bittenbinder, M.A., Somsen, G.W., Vonk, F.J., Casewell, N.R., and Kool, J. (2020). Neutralizing Effects of Small Molecule Inhibitors and Metal Chelators on Coagulopathic Viperinae Snake Venom Toxins. Biomedicines, 8. · doi:10.1101/2020.06.02.129643
  69. Xie, 2021, Erythrocyte Haemotoxicity Profiling of Snake Venom Toxins after Nanofractionation, J. Chromatogr. B, 1176, 122586, 10.1016/j.jchromb.2021.122586 · DOI
  70. Kazandjian, T.D., Arrahman, A., Still, K.B.M., Somsen, G.W., Vonk, F.J., Casewell, N.R., Wilkinson, M.C., and Kool, J. (2021). Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib. Toxins, 13. · DOI
  71. Barbosa, 2021, Quantum Biochemical Investigation of Lys49-PLA2 from Bothrops moojeni, J. Phys. Chem. B, 125, 12972, 10.1021/acs.jpcb.1c07298 · doi:10.1021/acs.jpcb.1c07298
  72. Ownby, 1999, Lysine 49 Phospholipase A2 Proteins, Toxicon, 37, 411, 10.1016/S0041-0101(98)00188-3 · DOI · Paper page
  73. White, 1996, Sequence Analysis of Lys49 Phospholipase A2 Myotoxins: A Highly Conserved Class of Proteins, Toxicon, 34, 1237, 10.1016/S0041-0101(96)00111-0 · doi:10.1016/s0041-0101(96)00111-0
  74. Chacur, 2004, Snake Venom Phospholipase A2s (Asp49 and Lys49) Induce Mechanical Allodynia upon Peri-Sciatic Administration: Involvement of Spinal Cord Glia, Proinflammatory Cytokines and Nitric Oxide, Pain, 108, 180, 10.1016/j.pain.2003.12.023 · DOI
  75. Gaspar, 2022, In Vivo Treatment with Varespladib, a Phospholipase A2 Inhibitor, Prevents the Peripheral Neurotoxicity and Systemic Disorders Induced by Micrurus Corallinus (Coral Snake) Venom in Rats, Toxicol. Lett., 356, 54, 10.1016/j.toxlet.2021.11.003 · DOI
  76. Gaspar, 2022, Partial Efficacy of a Brazilian Coralsnake Antivenom and Varespladib in Neutralizing Distinct Toxic Effects Induced by Sublethal Micrurus Dumerilii Carinicauda Envenoming in Rats, Toxicon, 213, 99, 10.1016/j.toxicon.2022.04.014 · DOI
  77. Tan, 2022, Varespladib (LY315920) Rescued Mice from Fatal Neurotoxicity Caused by Venoms of Five Major Asiatic Kraits (Bungarus Spp.) in an Experimental Envenoming and Rescue Model, Acta Trop., 227, 106289, 10.1016/j.actatropica.2021.106289 · DOI
  78. Lewin, 2020, Varespladib (LY315920) Inhibits Neuromuscular Blockade Induced by Oxyuranus Scutellatus Venom in a Nerve-Muscle Preparation, Toxicon, 187, 101, 10.1016/j.toxicon.2020.08.023 · DOI
  79. Maciel, 2021, Varespladib (LY315920) Prevents Neuromuscular Blockage and Myotoxicity Induced by Crotoxin on Mouse Neuromuscular Preparations, Toxicon, 202, 40, 10.1016/j.toxicon.2021.09.009 · DOI
  80. Oliveira, 2022, Effect of the Phospholipase A2 Inhibitor Varespladib, and Its Synergism with Crotalic Antivenom, on the Neuromuscular Blockade Induced by Crotalus Durissus Terrificus Venom (with and without Crotamine) in Mouse Neuromuscular Preparations, Toxicon, 214, 54, 10.1016/j.toxicon.2022.05.001 · DOI
  81. Zinenko, O., Tovstukha, I., and Korniyenko, Y. (2020). PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera Berus Nikolskii. Toxins, 12. · DOI
  82. Liu, 2021, Snake Venom Proteome of Protobothrops Mucrosquamatus in Taiwan: Delaying Venom-Induced Lethality in a Rodent Model by Inhibition of Phospholipase A2 Activity with Varespladib, J Proteomics, 234, 104084, 10.1016/j.jprot.2020.104084 · DOI
  83. Gutierres, P.G., Pereira, D.R., Vieira, N.L., Arantes, L.F., Silva, N.J., Torres-Bonilla, K.A., Hyslop, S., Morais-Zani, K., Nogueira, R.M.B., and Rowan, E.G. (2022). Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis Muta Rhombeata (South-American Bushmaster) Venom. Front. Pharmacol., 12. · DOI
  84. Albulescu, 2020, A Therapeutic Combination of Two Small Molecule Toxin Inhibitors Provides Broad Preclinical Efficacy against Viper Snakebite, Nat. Commun., 11, 6094, 10.1038/s41467-020-19981-6 · DOI · Paper page
  85. Youngman, 2020, Varespladib (LY315920) Neutralises Phospholipase A2 Mediated Prothrombinase-Inhibition Induced by Bitis Snake Venoms, Comp. Biochem. Physiol. Part C Toxicol. Pharmacol., 236, 108818, 10.1016/j.cbpc.2020.108818 · DOI
  86. Dashevsky, 2021, Anticoagulant Micrurus Venoms: Targets and Neutralization, Toxicol. Lett., 337, 91, 10.1016/j.toxlet.2020.11.010 · DOI
  87. Lomonte, 2014, Intravascular Hemolysis Induced by the Venom of the Eastern Coral Snake, Micrurus Fulvius, in a Mouse Model: Identification of Directly Hemolytic Phospholipases A2, Toxicon, 90, 26, 10.1016/j.toxicon.2014.07.010 · DOI
  88. Arrahman, A., Kazandjian, T.D., Still, K.B.M., Slagboom, J., Somsen, G.W., Vonk, F.J., Casewell, N.R., and Kool, J. (2022). A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib. Toxins, 14. · DOI

Cited by

See all 98

Metadata

Authors
Lewin, M. R., Carter, R. W., Matteo, I. A., Samuel, S. P., Rao, S., Fry, B. G., & Bickler, P. E.
Affiliations
  • Division of Research, Ophirex, Inc., Corte Madera, CA 94925, USA
  • Center for Exploration and Travel Health, California Academy of Sciences, San Francisco, CA 94118, USA
  • Venom Evolution Lab, School of Biological Science, University of Queensland, St. Lucia, QLD 4072, Australia
Venue
Toxins
Publisher
MDPI AG
Published
2022-11-11
Volume
14
Issue
11
Pages
783
ISSN
2072-6651
Cited by
98
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. https://app.cochat.ai/papers/10.3390/toxins14110783
The paper
Lewin, M. R., Carter, R. W., Matteo, I. A., Samuel, S. P., Rao, S., Fry, B. G., & Bickler, P. E. (2022). Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins. https://doi.org/10.3390/toxins14110783

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.